Zogenix (NASDAQ:ZGNX) announced its earnings results on Thursday. The company reported ($6.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.70), Briefing.com reports. The business had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.39 million. During the same quarter in the previous year, the business posted ($1.08) EPS.
Shares of ZGNX traded down $0.68 during trading hours on Friday, hitting $43.40. The stock had a trading volume of 532,200 shares, compared to its average volume of 565,004. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.19 and a current ratio of 7.19. The firm has a market cap of $1.98 billion, a P/E ratio of -13.44 and a beta of 1.94. The company’s fifty day simple moving average is $42.50 and its 200 day simple moving average is $43.03. Zogenix has a 12-month low of $33.43 and a 12-month high of $56.50.
In related news, EVP Gail M. Farfel sold 3,446 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $52.00, for a total value of $179,192.00. Following the transaction, the executive vice president now directly owns 4,891 shares of the company’s stock, valued at approximately $254,332. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.40% of the company’s stock.
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.
Featured Story: What is range trading?
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.